Stay updated with breaking news from Valerie morisset. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eliem Therapeutics (ELYM) will pause all further development of ETX-155 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M May 24, 2021 at 11:03 am Bob Azelby. (Eliem Photo) New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The fresh funding comes just two months after Eliem raised a $80 million round. The pipeline: Founded in 2019, the company has two lead drug candidates in development: ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures. Both are in Phase 2a clinical trials. ETX-810 is described as an investigational non-opioid that uses the palmitoylethanolamide (PEA) pathway to influence neuroinflammation and pain signaling. ETX-155 is an neuroactive steroid that acts as a GABA ....